CL2024002218A1 - Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico - Google Patents
Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásicoInfo
- Publication number
- CL2024002218A1 CL2024002218A1 CL2024002218A CL2024002218A CL2024002218A1 CL 2024002218 A1 CL2024002218 A1 CL 2024002218A1 CL 2024002218 A CL2024002218 A CL 2024002218A CL 2024002218 A CL2024002218 A CL 2024002218A CL 2024002218 A1 CL2024002218 A1 CL 2024002218A1
- Authority
- CL
- Chile
- Prior art keywords
- pharmaceutical composition
- administration
- antineoplastic drug
- composition including
- phthalazinone derivative
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 239000002246 antineoplastic agent Substances 0.000 title abstract 3
- 229940041181 antineoplastic drug Drugs 0.000 title abstract 3
- 238000011260 co-administration Methods 0.000 title abstract 2
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263302834P | 2022-01-25 | 2022-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024002218A1 true CL2024002218A1 (es) | 2024-12-20 |
Family
ID=87470837
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024002218A CL2024002218A1 (es) | 2022-01-25 | 2024-07-23 | Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250120970A1 (https=) |
| EP (1) | EP4469051A4 (https=) |
| JP (1) | JP2025505381A (https=) |
| KR (1) | KR20240138069A (https=) |
| CN (1) | CN118613264A (https=) |
| AU (1) | AU2023210923A1 (https=) |
| CA (1) | CA3249330A1 (https=) |
| CL (1) | CL2024002218A1 (https=) |
| IL (1) | IL314334A (https=) |
| JO (1) | JOP20240162A1 (https=) |
| MA (1) | MA66598A1 (https=) |
| MX (1) | MX2024009168A (https=) |
| TW (1) | TW202339753A (https=) |
| WO (1) | WO2023144626A1 (https=) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102372706A (zh) * | 2010-08-09 | 2012-03-14 | 江苏恒瑞医药股份有限公司 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
| EP2833883A4 (en) * | 2012-04-06 | 2015-12-23 | Indus Pharmaceuticals Inc | NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES |
| KR101670126B1 (ko) * | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
| US12036222B2 (en) * | 2018-04-04 | 2024-07-16 | The Wistar Institut of Anatomy and Biology | Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor |
| JP7626783B2 (ja) * | 2020-04-21 | 2025-02-07 | アイディーエンス カンパニー リミテッド | フタラジノン誘導体及びその中間体を調製するプロセス |
| AU2020444056A1 (en) * | 2020-04-21 | 2022-11-17 | Idience Co., Ltd. | Crystalline forms of phthalazinone compound |
-
2023
- 2023-01-25 EP EP23746538.0A patent/EP4469051A4/en active Pending
- 2023-01-25 CN CN202380018679.4A patent/CN118613264A/zh active Pending
- 2023-01-25 KR KR1020247022669A patent/KR20240138069A/ko active Pending
- 2023-01-25 MA MA66598A patent/MA66598A1/fr unknown
- 2023-01-25 CA CA3249330A patent/CA3249330A1/en active Pending
- 2023-01-25 JP JP2024543458A patent/JP2025505381A/ja active Pending
- 2023-01-25 WO PCT/IB2023/000030 patent/WO2023144626A1/en not_active Ceased
- 2023-01-25 IL IL314334A patent/IL314334A/en unknown
- 2023-01-25 US US18/730,930 patent/US20250120970A1/en active Pending
- 2023-01-25 AU AU2023210923A patent/AU2023210923A1/en active Pending
- 2023-01-25 MX MX2024009168A patent/MX2024009168A/es unknown
- 2023-01-30 TW TW112103190A patent/TW202339753A/zh unknown
-
2024
- 2024-07-23 JO JOJO/P/2024/0162A patent/JOP20240162A1/ar unknown
- 2024-07-23 CL CL2024002218A patent/CL2024002218A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA66598A1 (fr) | 2024-11-29 |
| WO2023144626A1 (en) | 2023-08-03 |
| JOP20240162A1 (ar) | 2024-07-23 |
| CN118613264A (zh) | 2024-09-06 |
| EP4469051A4 (en) | 2025-12-17 |
| MX2024009168A (es) | 2024-08-09 |
| IL314334A (en) | 2024-09-01 |
| EP4469051A1 (en) | 2024-12-04 |
| US20250120970A1 (en) | 2025-04-17 |
| JP2025505381A (ja) | 2025-02-26 |
| TW202339753A (zh) | 2023-10-16 |
| KR20240138069A (ko) | 2024-09-20 |
| AU2023210923A1 (en) | 2024-07-25 |
| CA3249330A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20210401A1 (es) | Composiciones farmaceuticas que comprenden meloxicam | |
| MX2021009646A (es) | Uso de cannabinoides en el tratamiento de epilepsia. | |
| AR054064A1 (es) | Composicio con ingrediente farmaceutico activo en base a canabinoide para formas de dosis mejoradas | |
| UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CO2022008606A2 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| BR112021018169A2 (pt) | Composto para o controle de diabetes de felinos | |
| BR112022019864A2 (pt) | Composto de oxofenilarsina deuterada e uso do mesmo | |
| CO2022003583A2 (es) | Compuestos de curcumina y aminoácidos básicos | |
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| CO2021005221A2 (es) | Formulación basada en ciclodextrina de un inhibidor de bcl-2 | |
| CL2024002218A1 (es) | Composición farmacéutica que incluye derivado de ftalazinona para coadministración con fármaco antineoplásico | |
| CO2020001887A2 (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático | |
| BR112022026558A2 (pt) | Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo | |
| CO2023000194A2 (es) | Administración de sulcardina para el tratamiento de fibrilación auricular aguda | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| WO2018217735A3 (en) | HIGH CONCENTRATION FULVESTRANT COMPOSITIONS | |
| UY38589A (es) | Composición farmacéutica liofilizada de antiinflamatorio no esteroideo | |
| TR202010528A2 (tr) | Oksi̇dati̇f stresi̇n azaltilmasi i̇çi̇n bi̇r bi̇leşi̇k | |
| CO2025014537A2 (es) | Fórmula combinada que comprende sacubitrilo-valsartán e inhibidor del sglt-2 con estabilidad y velocidad de disolución mejoradas | |
| WO2020036478A3 (es) | Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas | |
| JOP20250173A1 (ar) | مثبط بروتين أرجينين مثيل ترانسفيراز 5-مثيل ثيوأدينوزين | |
| AR123553A1 (es) | Formas farmacéuticas sólidas con perfiles de disgregación mejorados | |
| MX2025007429A (es) | Composiciones para la prevencion y el tratamiento de la insuficiencia renal (rf) |